Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial

Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial

Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Retrospective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2018-11, Vol.24 (21), p.5305-5312
Hauptverfasser: Toren, Paul, Hoffman, Azik, Ding, Keyue, Joncas, France-Hélène, Turcotte, Veronique, Caron, Patrick, Pouliot, Frédéric, Fradet, Yves, Levesque, Eric, Guillemette, Chantal, Klotz, Laurence H
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 5312
container_issue 21
container_start_page 5305
container_title Clinical cancer research
container_volume 24
creator Toren, Paul
Hoffman, Azik
Ding, Keyue
Joncas, France-Hélène
Turcotte, Veronique
Caron, Patrick
Pouliot, Frédéric
Fradet, Yves
Levesque, Eric
Guillemette, Chantal
Klotz, Laurence H
description Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Retrospective cohort study of Canadian patients in the PR.7 trial (accrual 1999-2005) who received continuous ADT for biochemical recurrence post-radiotherapy. Patients were excluded with follow-up
doi_str_mv 10.1158/1078-0432.CCR-18-1187
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2072187095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2072187095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2717-411ffeebddc40ef2251c8b72a7c8147b0f02dd8d03d5a0e2ab4deaf0e7baf9f73</originalsourceid><addsrcrecordid>eNo9kc1u1TAQhS0Eor-PAJolm1w8ToJz2aGrQpEqgdqythx73Bpy7WA7Ffd5eFEctWVla_SdY885jL1BvkHsh_fI5dDwrhWb3e66waFBHOQLdox9L5tWfOhf1vszc8ROcv7JOXbIu9fsqOVc4BbxmP29obTsIdMfyIVS9DaDzjCneBdiLt7A6ONep1-UMvgAsy6eQsmQyJB_8OEOdLCVpgCW5uQfKhADlHtKej6Ai2lFl5SqarXNRRcCo4Oh9BE0zHXS3EdTbfR0yD5DdKsavl9vJJTk9XTGXjk9ZTp_Ok_Zj88Xt7vL5urbl6-7T1eNERJl0yE6RzRaazpOTogezTBKoaUZsJMjd1xYO1je2l5zEnrsLGnHSY7abZ1sT9m7R9_6zd8L5aL2PhuaJh0oLlkJLkUNmW_7ivaPqKkb5URO1dVrTAeFXK39qDV7tWavaj8K66BKq-7t0xPLuCf7X_VcSPsP92mQsA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2072187095</pqid></control><display><type>article</type><title>Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial</title><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Toren, Paul ; Hoffman, Azik ; Ding, Keyue ; Joncas, France-Hélène ; Turcotte, Veronique ; Caron, Patrick ; Pouliot, Frédéric ; Fradet, Yves ; Levesque, Eric ; Guillemette, Chantal ; Klotz, Laurence H</creator><creatorcontrib>Toren, Paul ; Hoffman, Azik ; Ding, Keyue ; Joncas, France-Hélène ; Turcotte, Veronique ; Caron, Patrick ; Pouliot, Frédéric ; Fradet, Yves ; Levesque, Eric ; Guillemette, Chantal ; Klotz, Laurence H</creatorcontrib><description>Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Retrospective cohort study of Canadian patients in the PR.7 trial (accrual 1999-2005) who received continuous ADT for biochemical recurrence post-radiotherapy. Patients were excluded with follow-up &lt;2 years or who received estrogens or corticosteroids. Kaplan-Meier and multivariable cox regression analyses adjusted for baseline prognostic factors assessed time to castration resistance prostate cancer(CRPC), prostate cancer survival and overall survival according to tertile of sex steroid measured by mass spectrometry. Post-ADT initiation, we measured samples in 219 patients as well as 2 subsequent annual samples in a subset of 101 patients. Testosterone levels correlated with androstenedione (AD) and dihydrotestosterone (DHT), while DHT, AD, androsterone (AST), dehydroepiandrosterone (DHEA) and androstenediol (A5diol) were highly correlated to each other and negatively associated with age. Higher tertiles of estrone(E ) and estradiol(E ) were significantly associated with sooner time to CRPC. In patients with longitudinal samples, increases in serum DHEA and AST were significantly associated with sooner time to CRPC. Limitations include the number of events for some groups. Our data suggest the patient hormonal milieu has long-term prognostic value in men receiving ADT for recurrent prostate cancer, including increased levels of E and E and rising DHEA and AST levels which predict a shorter time to CRPC.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-18-1187</identifier><identifier>PMID: 30021911</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical cancer research, 2018-11, Vol.24 (21), p.5305-5312</ispartof><rights>Copyright ©2018, American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2717-411ffeebddc40ef2251c8b72a7c8147b0f02dd8d03d5a0e2ab4deaf0e7baf9f73</citedby><cites>FETCH-LOGICAL-c2717-411ffeebddc40ef2251c8b72a7c8147b0f02dd8d03d5a0e2ab4deaf0e7baf9f73</cites><orcidid>0000-0002-0524-7892 ; 0000-0003-4035-2935 ; 0000-0002-5762-5787</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30021911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toren, Paul</creatorcontrib><creatorcontrib>Hoffman, Azik</creatorcontrib><creatorcontrib>Ding, Keyue</creatorcontrib><creatorcontrib>Joncas, France-Hélène</creatorcontrib><creatorcontrib>Turcotte, Veronique</creatorcontrib><creatorcontrib>Caron, Patrick</creatorcontrib><creatorcontrib>Pouliot, Frédéric</creatorcontrib><creatorcontrib>Fradet, Yves</creatorcontrib><creatorcontrib>Levesque, Eric</creatorcontrib><creatorcontrib>Guillemette, Chantal</creatorcontrib><creatorcontrib>Klotz, Laurence H</creatorcontrib><title>Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Retrospective cohort study of Canadian patients in the PR.7 trial (accrual 1999-2005) who received continuous ADT for biochemical recurrence post-radiotherapy. Patients were excluded with follow-up &lt;2 years or who received estrogens or corticosteroids. Kaplan-Meier and multivariable cox regression analyses adjusted for baseline prognostic factors assessed time to castration resistance prostate cancer(CRPC), prostate cancer survival and overall survival according to tertile of sex steroid measured by mass spectrometry. Post-ADT initiation, we measured samples in 219 patients as well as 2 subsequent annual samples in a subset of 101 patients. Testosterone levels correlated with androstenedione (AD) and dihydrotestosterone (DHT), while DHT, AD, androsterone (AST), dehydroepiandrosterone (DHEA) and androstenediol (A5diol) were highly correlated to each other and negatively associated with age. Higher tertiles of estrone(E ) and estradiol(E ) were significantly associated with sooner time to CRPC. In patients with longitudinal samples, increases in serum DHEA and AST were significantly associated with sooner time to CRPC. Limitations include the number of events for some groups. Our data suggest the patient hormonal milieu has long-term prognostic value in men receiving ADT for recurrent prostate cancer, including increased levels of E and E and rising DHEA and AST levels which predict a shorter time to CRPC.</description><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNo9kc1u1TAQhS0Eor-PAJolm1w8ToJz2aGrQpEqgdqythx73Bpy7WA7Ffd5eFEctWVla_SdY885jL1BvkHsh_fI5dDwrhWb3e66waFBHOQLdox9L5tWfOhf1vszc8ROcv7JOXbIu9fsqOVc4BbxmP29obTsIdMfyIVS9DaDzjCneBdiLt7A6ONep1-UMvgAsy6eQsmQyJB_8OEOdLCVpgCW5uQfKhADlHtKej6Ai2lFl5SqarXNRRcCo4Oh9BE0zHXS3EdTbfR0yD5DdKsavl9vJJTk9XTGXjk9ZTp_Ok_Zj88Xt7vL5urbl6-7T1eNERJl0yE6RzRaazpOTogezTBKoaUZsJMjd1xYO1je2l5zEnrsLGnHSY7abZ1sT9m7R9_6zd8L5aL2PhuaJh0oLlkJLkUNmW_7ivaPqKkb5URO1dVrTAeFXK39qDV7tWavaj8K66BKq-7t0xPLuCf7X_VcSPsP92mQsA</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Toren, Paul</creator><creator>Hoffman, Azik</creator><creator>Ding, Keyue</creator><creator>Joncas, France-Hélène</creator><creator>Turcotte, Veronique</creator><creator>Caron, Patrick</creator><creator>Pouliot, Frédéric</creator><creator>Fradet, Yves</creator><creator>Levesque, Eric</creator><creator>Guillemette, Chantal</creator><creator>Klotz, Laurence H</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0524-7892</orcidid><orcidid>https://orcid.org/0000-0003-4035-2935</orcidid><orcidid>https://orcid.org/0000-0002-5762-5787</orcidid></search><sort><creationdate>20181101</creationdate><title>Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial</title><author>Toren, Paul ; Hoffman, Azik ; Ding, Keyue ; Joncas, France-Hélène ; Turcotte, Veronique ; Caron, Patrick ; Pouliot, Frédéric ; Fradet, Yves ; Levesque, Eric ; Guillemette, Chantal ; Klotz, Laurence H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2717-411ffeebddc40ef2251c8b72a7c8147b0f02dd8d03d5a0e2ab4deaf0e7baf9f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toren, Paul</creatorcontrib><creatorcontrib>Hoffman, Azik</creatorcontrib><creatorcontrib>Ding, Keyue</creatorcontrib><creatorcontrib>Joncas, France-Hélène</creatorcontrib><creatorcontrib>Turcotte, Veronique</creatorcontrib><creatorcontrib>Caron, Patrick</creatorcontrib><creatorcontrib>Pouliot, Frédéric</creatorcontrib><creatorcontrib>Fradet, Yves</creatorcontrib><creatorcontrib>Levesque, Eric</creatorcontrib><creatorcontrib>Guillemette, Chantal</creatorcontrib><creatorcontrib>Klotz, Laurence H</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toren, Paul</au><au>Hoffman, Azik</au><au>Ding, Keyue</au><au>Joncas, France-Hélène</au><au>Turcotte, Veronique</au><au>Caron, Patrick</au><au>Pouliot, Frédéric</au><au>Fradet, Yves</au><au>Levesque, Eric</au><au>Guillemette, Chantal</au><au>Klotz, Laurence H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>24</volume><issue>21</issue><spage>5305</spage><epage>5312</epage><pages>5305-5312</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Phenotypic biomarkers are a high priority for patients receiving androgen deprivation therapy (ADT) for prostate cancer given the increasing number of treatment options. This study evaluates serum sex steroids as prognostic biomarkers in men receiving ADT for recurrent prostate cancer. Retrospective cohort study of Canadian patients in the PR.7 trial (accrual 1999-2005) who received continuous ADT for biochemical recurrence post-radiotherapy. Patients were excluded with follow-up &lt;2 years or who received estrogens or corticosteroids. Kaplan-Meier and multivariable cox regression analyses adjusted for baseline prognostic factors assessed time to castration resistance prostate cancer(CRPC), prostate cancer survival and overall survival according to tertile of sex steroid measured by mass spectrometry. Post-ADT initiation, we measured samples in 219 patients as well as 2 subsequent annual samples in a subset of 101 patients. Testosterone levels correlated with androstenedione (AD) and dihydrotestosterone (DHT), while DHT, AD, androsterone (AST), dehydroepiandrosterone (DHEA) and androstenediol (A5diol) were highly correlated to each other and negatively associated with age. Higher tertiles of estrone(E ) and estradiol(E ) were significantly associated with sooner time to CRPC. In patients with longitudinal samples, increases in serum DHEA and AST were significantly associated with sooner time to CRPC. Limitations include the number of events for some groups. Our data suggest the patient hormonal milieu has long-term prognostic value in men receiving ADT for recurrent prostate cancer, including increased levels of E and E and rising DHEA and AST levels which predict a shorter time to CRPC.</abstract><cop>United States</cop><pmid>30021911</pmid><doi>10.1158/1078-0432.CCR-18-1187</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-0524-7892</orcidid><orcidid>https://orcid.org/0000-0003-4035-2935</orcidid><orcidid>https://orcid.org/0000-0002-5762-5787</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2018-11, Vol.24 (21), p.5305-5312
issn 1078-0432
1557-3265
language eng
recordid cdi_proquest_miscellaneous_2072187095
source American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A47%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20sex%20steroids%20as%20prognostic%20biomarkers%20in%20patients%20receiving%20androgen%20deprivation%20therapy%20for%20recurrent%20prostate%20cancer:%20a%20post-hoc%20analysis%20of%20the%20PR.7%20trial&rft.jtitle=Clinical%20cancer%20research&rft.au=Toren,%20Paul&rft.date=2018-11-01&rft.volume=24&rft.issue=21&rft.spage=5305&rft.epage=5312&rft.pages=5305-5312&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-18-1187&rft_dat=%3Cproquest_cross%3E2072187095%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2072187095&rft_id=info:pmid/30021911&rfr_iscdi=true